My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

3.930 -0.360 (-8.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers CynergisTek, Inc. (NYSE: CTEK) jumped 100% to $1.18 after the company entered into a definitive agreement to be acquired by Clearwater Compliance for roughly $17.7 million. 
Via Benzinga
Psychedelic Treatment For Alcoholism? Clearmind Medicine And SciSparc Collaboration Yields Positive Results
Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems,... 
Via Benzinga
SciSparc And Clearmind Medicine Inc. Collaboration Yields Positive Results For Its Psychedelic Combination Treatment
Pre-clinical trials based on the proprietary combination demonstrate significant suppressive effect on alcohol consumption 
Via Benzinga
SciSparc Issued Israeli Patent For Its Core Technology For Treating Central Nervous Systems Disorders
Patent extends protection for SciSparc’s novel compounds and methods already granted in the US, Australia and Japan 
Via Benzinga
SciSparc Files Annual Report For Year Ended December 31, 2021 And Provides Corporate Update
TEL AVIV, Israel, May 2, 2022 /PRNewswire/ -- SciSparc Ltd. 
Via Benzinga
Global Psychedelics Market Is Expected To Reach $8 Billion By 2029
Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster... 
Via FinancialNewsMedia
SciSparc Reports Developing Cannabinoids Based Acute Pain Relief Alternative To Help Counter Opioid Crisis
Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Has Clearmind Developed A Psychedelics-Based Drug That Can Treat Alcoholism? The FDA Is Interested
On Wednesday, May 18, Clearmind Medicine Inc. (OTC Pink: CMNDF) will meet with the Center for Drug Evaluation and Research (CDER), a department within the FDA. 
Via Benzinga
23 Stocks Moving in Friday's Pre-Market Session
Gainers OTR Acquisition Corp. (NASDAQ: OTRA) rose 88.7% to $18.21 in pre-market trading after filing on Thursday showed shareholders approved merger with Comera Life Sciences. 
Via Benzinga
90 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered... 
Via Benzinga
The Hidden Potential Of The Endocannabinoid System? SciSparc Says Its Portfolio Of Cannabinoids-Derived Drug Candidates Tap The Body's Natural System
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Originally motivated by a belief in the dangerous effects... 
Via Benzinga
SciSparc And Clearmind Reveal Potential To Reduce Alcohol Consumption With Psychedelic Treatment In New Patent Application
Image by Thom Masat on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
SciSparc And Clearmind Medicine Inc. Collaboration Yields New Patent Application For Psychedelic Combination Treatment For Binge Behaviors
Preclinical study results demonstrated the combination of SciSparc's CannAmide™ with Clearmind's MEAI has the potential to reduce alcohol consumption 
Via Benzinga
12 Stocks Halted On A Circuit Breaker This Week
A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and... 
Via Benzinga
36 Stocks Moving In Friday's Mid-Day Session
Gainers Forge Global Holdings, Inc. (NYSE: FRGE) shares jumped 66.4% to $20.70. Clever Leaves Holdings Inc. (NASDAQ: CLVR) jumped 29.1% to $2.04 after the company reported... 
Via Benzinga
55 Biggest Movers From Friday
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; US Pending Home Sales Index Drop 4.1%
U.S. stocks traded opened on a mixed note this morning, with the Dow Jones gaining around 80 points on Friday. Following the market opening, the Dow traded up 0.25% to 34,795.46... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) shares gained 81.3% to close at $2.32 on Monday. Last week, AMC Entertainment Holdings purchased a major stake in... 
Via Benzinga
Alcoholism & Psychedelics: Clearmind Trials Reveal Certain Psychedelics Help Reduce Alcohol Consumption In Mice
Clearmind Medicine Inc. 
Via Benzinga
Clearmind Medicine, SciSparc Launch A Psychedelic Pharma Collaboration
Psychedelic-focused biotech company Clearmind Medicine Inc. (CSE:CMND) (OTC: CMNDF) has signed a collaboration agreement with ... 
Via Benzinga
68 Biggest Movers From Yesterday
Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday. Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 39.2% to... 
Via Benzinga
Meet a Company Harnessnessing the Power of Synergy for its Drug Therapeutics
Photo by Roberto Sorin on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.... 
Via Benzinga
SciSparc Has Been Granted The Patent in the United States for its Core Technology, Used to Treat Central Nervous System Disorders.
Via AB Newswire
Topics Intellectual Property
Advances for Tourette Syndrome, Alzheimer’s Disease, Pain Management, Autism Spectrum Disorder and Epilepsy from Proprietary Compounds: SciSparc Ltd. (NASDAQ: SPRC)
Via Get News
Advances for Tourette Syndrome, Alzheimer's Disease, Pain Management, Autism Spectrum Disorder and Epilepsy from Proprietary Compounds: SciSparc Ltd. (NASDAQ: SPRC) SPRC Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems
Via Viz Release
Topics Intellectual Property
Pharmaceutical company SciSparc Ltd to make progress in treating nervous system disorders in 2022
Via AB Newswire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.